Skip to content

State coverage

Nebraska

State Medicaid · 4 documents cited

Medicaid, for obesity: Covers with conditions. The conditions and the appeal deadline are in the summary below.

At a glance

Covers with conditions
Medicaid, for obesity
Both drugs are off the standard list, each with its own pathway: Wegovy for heart risk, Zepbound for sleep apnea.
Appeal deadline
60 days from the date on your denial notice to appeal to your health plan, then 120 days from that plan's decision to ask for a state fair hearing source
Primary source
Nebraska Department of Health and Human Services, Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria
Date read
September 2026

Denise Ramirez, Coverage Editor · Who writes this site

Nebraska's standard Preferred Drug List handles GLP-1s strictly as diabetes drugs. Its diabetic GLP-1 class covers Ozempic, Trulicity and Victoza as preferred agents and Mounjaro, Rybelsus and Bydureon BCise as non-preferred, each gated behind a documented type 2 diabetes diagnosis. Wegovy, Zepbound and Saxenda do not appear anywhere in the 97-page list, under any heading. Read alone, that would look like a flat exclusion.

It is not the whole picture. Nebraska Medicaid runs two separate, drug-specific prior authorization forms for exactly these two products, entirely outside the standard drug-list process. The Wegovy form states its own scope on the first page: coverage for reducing cardiovascular risk in adults 45 to 74, or for treating a liver condition called MASH. No box on the form exists for a weight-loss-only request. The Zepbound form is narrower still and says so bluntly: tirzepatide is covered only for moderate-to-severe obstructive sleep apnea, and only after documented failure or intolerance of CPAP therapy.

The age band on the Wegovy pathway — 45 to 74 — is unusual; most states writing a cardiovascular-risk carve-out for these drugs set no upper age bound at all. Nebraska's form does not explain the ceiling, and nothing else read here does either.

One limit is worth stating plainly, because it is about our sources rather than about Nebraska. The appeal deadline below is quoted from the state's own Heritage Health program page, addressed to the reader and giving DHHS's own filing address, rather than from the administrative code chapter that presumably sets it. That chapter, 482 NAC ch. 7, could not be located on a Nebraska government host on 2026-09-03. The figures below are the ones the state publishes to members; they were not checked against the regulation's own text.

What we could verify for Nebraska

The state's drug list carries a "Diabetic GLP-1/GIP and Combos" class listing "Ozempic," "Trulicity" and "Victoza" as preferred and "Bydureon BCISE," "exenatide pen (gen Byetta)," "liraglutide (gen Victoza)," "Mounjaro" and "Rybelsus" as non-preferred, each requiring a diagnosis of type 2 diabetes and, for non-preferred agents, a documented trial of metformin first. Neither Wegovy, Zepbound nor Saxenda is named anywhere in this 97-page document, under this or any other heading.

Nebraska Department of Health and Human Services, Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria, effective January 2026 · source

Nebraska's drug-specific prior authorization form states its scope on page one: "Semaglutide (Wegovy) is covered for the reduction of the risk of major adverse cardiovascular events (MACE) (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults 45 to 74 years of age, or for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults at least 18 years of age." The cardiovascular pathway also requires either "An initial BMI of at least 27 kg/m2 and at least one weight-related comorbid condition" or "An initial BMI of at least 30 kg/m2," plus six months of a physician-supervised weight-management program before initial approval.

Nebraska Department of Health and Human Services, Nebraska Medicaid Fee-For-Service Pharmacy Benefit, Request for Prior Authorization — Wegovy (semaglutide), effective January 2026 · source

Nebraska's Zepbound-specific form is more restrictive and says so directly: "Tirzepatide (Zepbound) is only covered for the treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults aged at least 18 years." Initial approval requires an initial BMI of at least 30, six months of a supervised weight-management program including "Counseling to avoid sleeping in the supine position" and "Counseling to avoid alcohol and sedatives before bedtime," and documentation that the member has been treated with positive airway pressure therapy and either failed to reach therapeutic goals on it or could not tolerate it.

Nebraska Medicaid Program, Request for Prior Authorization — Anti-Obesity Medication (Zepbound/tirzepatide), effective July 2025 · source

Nebraska's Heritage Health program states two appeal clocks: "You have sixty (60) days from the date on your notice of adverse benefit determination to request an appeal with your health plan... You have 120 days from the date on the notice of resolution for the health plan appeal to request a State Fair Hearing." Requests for a state fair hearing go in writing to "Department of Health and Human Services, MLTC Appeal Coordinator, PO Box 94967, Lincoln, NE 68509-4967."

Nebraska Department of Health and Human Services, Heritage Health program · source

Medicaid is only one of the routes. If you have a commercial or employer plan, the rules are different and are on the employer plans page; Medicare has a federal rule of its own, on the Part D page.

If the appeal fails, or you cannot wait

Cash-pay telehealth is the fallback, not the bargain: you pay the whole cost yourself, and a covered prescription is almost always cheaper than any of these. Use this route when coverage has actually been exhausted, or when you need to start while an appeal runs.

Companies that pay this site a commission, what we found on each one's own site, and a link to check availability
CompanyWhat we found on its own site
CoreAge RxCheck availabilityAdvertises $99 a month for compounded semaglutide, flat across doses. Read the terms before you sign up: the lander our link opens has shown $149 rather than $99, and a consultation fee can be charged on top and may not be refundable.
OakCheck availabilityFlat price across doses, free shipping with supplies.
Care Bare RxCheck availabilityNames its pharmacies with addresses; sells brand Ozempic as well as compounded.
Gala HealthCheck availabilityAll doses one price, but the advertised rate needs a yearly subscription.
Synergy RxCheck availabilityProviders licensed in your state; publishes no GLP-1 price before the consult.
Breeze MedsCheck availabilityServes all 50 states; publishes a starting price only.
Direct MedsCheck availabilityNo monthly membership, and one price at every dose. The lander our link opens starts at $147 and reads its own discount two ways on the same screen: the banner across the top says $150 off, the product tiles below it say up to $200 off.
FoundCheck availabilityBills the clinical visits through insurance where it is in network, with the medication charged separately. Read its Medicare Part D route closely: it advertises brand GLP-1s from $50 a month, and the footnote under that offer says the $50 does not count toward your Part D deductible or out-of-pocket maximum, and that Extra Help does not apply.
EdenCheck availabilityTwo different prices for the same drug depending on which door you come in. The lander our link opens advertises $99 a month for semaglutide, held at every dose, with no membership fee. Eden's own weight-loss page, read the same day, offers it from $99 a month plus an Eden Membership, and the footnote there says the membership is $39 the first month and $99 after, and that medication is not available without one.
ShedRxCheck availabilityPublishes no price before the questionnaire: you answer it, pick a plan and see the cost at checkout. Sells injections plus needle-free drops and lozenges, and a footnote on the same page names sixteen states where the oral forms are not available.
TrimiCheck availabilityCompounded tirzepatide at $125 a month and semaglutide at $99, each on the annual plan and each the same price at every dose. One membership covers the medication, the clinician visits and shipping.
He & She MDCheck availabilityAdvertises semaglutide from $99 a month and charges only if a prescription is written. The printed tiers are higher than the headline: $139 a month on six months, billed $834 at once, and $149 a month on three. GLP-1s ship to every state except Louisiana.
HealthRXCheck availabilityCompounded semaglutide from $133 a month on a three-month plan and as low as $99 on twelve; tirzepatide from $209, as low as $179. ⚠ The page states its member reviews are illustrative composites rather than real patients.
Pallas HealthCheck availabilityCompounded semaglutide at $139 for the first month and then $597 every twelve weeks, and tirzepatide at $179 then $897. ⚠ The page discloses that some of its content is AI-generated and that its imagery uses models rather than patients.
MEDGmCheck availabilityGLP-1 injections from $179 and tablets from $249, with brand-name options priced as a membership plus the cost of the drug — $99 for Zepbound or Wegovy, $171 for Ozempic. ⚠ It discloses AI-generated content and actor imagery beside more than twenty named patient testimonials.
Bodybuilding Health+Check availabilityCompounded tirzepatide runs $174.67 to $209 a month depending how many months are bought at once, and semaglutide is tiered the same way. ⚠ The program is listed as Bodybuilding.com; the page this link opens brands itself Bodybuilding Health+ and is operated by Dynamo Group LLC.
Strut HealthCheck availabilityA multi-category telehealth storefront — sexual health, testosterone, hair, skin, peptides, menopause — where weight loss is one tile among six. It publishes no price for a GLP-1, or for anything else, on the page this link opens.
RxSpan MDCheck availabilityMulti-category telehealth that promises transparent pricing and no hidden fees, and then publishes no price at all — not for a GLP-1 and not for any other product — on the page this link opens.

Prices in those notes were read from each company's own site in August 2026 and September 2026, and they change often. Check the current number before you buy.

Where this comes from

  1. Nebraska Department of Health and Human Services, Nebraska Medicaid Preferred Drug List with Prior Authorization Criteria, effective January 2026 — nebraska.fhsc.com/downloads/PDL/NE_PDL-20260116.pdf
  2. Nebraska Department of Health and Human Services, Nebraska Medicaid Fee-For-Service Pharmacy Benefit, Request for Prior Authorization — Wegovy (semaglutide), effective January 2026 — nebraska.fhsc.com/Downloads/NEfaxform_anti-obesity_Wegovy.pdf
  3. Nebraska Medicaid Program, Request for Prior Authorization — Anti-Obesity Medication (Zepbound/tirzepatide), effective July 2025 — nebraska.fhsc.com/Downloads/NEfaxform_anti-obesity_Zepbound.pdf
  4. Nebraska Department of Health and Human Services, Heritage Health program — www.neheritagehealth.com/resources/appeals

Every state we have verified is in the coverage matrix. Appeal routes and deadlines are on the procedures page.